Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer

被引：13

作者：

Griguolo, Gaia ^{[1
,2
]}

Dieci, Maria Vittoria ^{[1
,2
]}

Pare, Laia ^{[3
,4
]}

Miglietta, Federica ^{[1
,2
]}

Generali, Daniele Giulio ^{[5
]}

Frassoldati, Antonio ^{[6
]}

Cavanna, Luigi ^{[7
]}

Bisagni, Giancarlo ^{[8
]}

Piacentini, Federico ^{[9
]}

Tagliafico, Enrico ^{[10
]}

Cagossi, Katia ^{[11
]}

Ficarra, Guido ^{[12
]}

Prat, Aleix ^{[3
,4
]}

Conte, Pierfranco ^{[1
,2
]}

Guarneri, Valentina ^{[1
,2
]}

机构：

[1] Univ Padua, Dept Surg Oncol & Gastroenterol, Padua, Italy

[2] Ist Oncol Veneto IOV IRCCS, Div Oncol 2, Padua, Italy

[3] Hosp Clin Barcelona, IDIBAPS, Div Oncol, Barcelona, Spain

[4] SOLTI Breast Canc Res Grp, Barcelona, Spain

[5] AO Ist Ospitalieri Cremona, Multidisciplinary Unit Breast Pathol, Cremona, Italy

[6] S Anna Univ Hosp, Dept Morphol Surg & Expt Med, Clin Oncol, Ferrara, Italy

[7] Piacenza Gen Hosp, Dept Hematol & Oncol, Oncol Unit, Piacenza, Italy

[8] Azienda Unita Sanit Locale IRCCS Reggio Emil, Dept Oncol & Adv Technol, Oncol Unit, Reggio Emilia, Italy

[9] Univ Hosp Modena, Dept Med & Surg Sci Children & Adults, Div Med Oncol, Modena, Italy

[10] Univ Modena & Reggio Emilia, Ctr Genome Res, Modena, Italy

[11] Ramazzini Hosp, Breast Unit, Carpi, Italy

[12] Azienda Osped Univ Policlin Modena, Dept Pathol, Modena, Italy

来源：

NPJ BREAST CANCER | 2021年 / 7卷 / 01期

关键词：

TUMOR-INFILTRATING LYMPHOCYTES; NEOADJUVANT; THERAPY;

D O I：

10.1038/s41523-021-00223-x

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Little is known regarding the interaction between immune microenvironment and tumor biology in hormone receptor (HR)+/HER2- breast cancer (BC). We here assess pretreatment gene-expression data from 66 HR+/HER2- early BCs from the LETLOB trial and show that non-luminal tumors (HER2-enriched, Basal-like) present higher tumor-infiltrating lymphocyte levels than luminal tumors. Moreover, significant differences in immune infiltrate composition, assessed by CIBERSORT, were observed: non-luminal tumors showed a more proinflammatory antitumor immune infiltrate composition than luminal ones.

引用

页数：5

共 50 条

[1] Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer
Gaia Griguolo
Maria Vittoria Dieci
Laia Paré
Federica Miglietta
Daniele Giulio Generali
Antonio Frassoldati
Luigi Cavanna
Giancarlo Bisagni
Federico Piacentini
Enrico Tagliafico
Katia Cagossi
Guido Ficarra
Aleix Prat
Pierfranco Conte
Valentina Guarneri
npj Breast Cancer, 7
[2] Immunotherapy for hormone receptor-positive HER2-negative breast cancer
Cardoso, Fatima
Hirshfield, Kim M.
Kraynyak, Kimberly A.
Tryfonidis, Konstantinos
Bardia, Aditya
NPJ BREAST CANCER, 2024, 10 (01)
[3] Neoadjuvant therapy in hormone Receptor-Positive/HER2-Negative breast cancer
Cantini, Luca
Trapani, Dario
Guidi, Lorenzo
Bielo, Luca Boscolo
Scafetta, Roberta
Koziej, Marcin
Vidal, Laura
Saini, Kamal S.
Curigliano, Giuseppe
CANCER TREATMENT REVIEWS, 2024, 123
[4] EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer
K. Almstedt
S. Mendoza
M. Otto
M. J. Battista
J. Steetskamp
A. S. Heimes
S. Krajnak
A. Poplawski
A. Gerhold-Ay
A. Hasenburg
C. Denkert
M. Schmidt
Breast Cancer Research and Treatment, 2020, 182 : 137 - 146
[5] Molecular classification of hormone receptor-positive HER2-negative breast cancer
Jin, Xi
Zhou, Yi-Fan
Ma, Ding
Zhao, Shen
Lin, Cai-Jin
Xiao, Yi
Fu, Tong
Liu, Cheng-Lin
Chen, Yi-Yu
Xiao, Wen-Xuan
Liu, Ya-Qing
Chen, Qing-Wang
Yu, Ying
Shi, Le-Ming
Shi, Jin-Xiu
Huang, Wei
Robertson, John F. R.
Jiang, Yi-Zhou
Shao, Zhi-Ming
NATURE GENETICS, 2023, 55 (10) : 1696 - +
[6] Management of hormone receptor-positive, HER2-negative early breast cancer
Walsh, Elaine M.
Smith, Karen L.
Stearns, Vered
SEMINARS IN ONCOLOGY, 2020, 47 (04) : 187 - 200
[7] Molecular classification of hormone receptor-positive HER2-negative breast cancer
Xi Jin
Yi-Fan Zhou
Ding Ma
Shen Zhao
Cai-Jin Lin
Yi Xiao
Tong Fu
Cheng-Lin Liu
Yi-Yu Chen
Wen-Xuan Xiao
Ya-Qing Liu
Qing-Wang Chen
Ying Yu
Le-Ming Shi
Jin-Xiu Shi
Wei Huang
John F. R. Robertson
Yi-Zhou Jiang
Zhi-Ming Shao
Nature Genetics, 2023, 55 : 1696 - 1708
[8] Clinical implications of the intrinsic molecular subtypes in hormone receptor-positive and HER2-negative metastatic breast cancer
Falato, Claudette
Schettini, Francesco
Pascual, Tomas
Braso-Maristany, Fara
Prat, Aleix
CANCER TREATMENT REVIEWS, 2023, 112
[9] EndoPredict(R) in early hormone receptor-positive, HER2-negative breast cancer
Almstedt, K.
Mendoza, S.
Otto, M.
Battista, M. J.
Steetskamp, J.
Heimes, A. S.
Krajnak, S.
Poplawski, A.
Gerhold-Ay, A.
Hasenburg, A.
Denkert, C.
Schmidt, M.
BREAST CANCER RESEARCH AND TREATMENT, 2020, 182 (01) : 137 - 146
[10] Hormone receptor-positive, HER2-negative metastatic breast cancer: redrawing the lines
Matutino, A.
Joy, A. A.
Brezden-Masley, C.
Chia, S.
Verma, S.
CURRENT ONCOLOGY, 2018, 25 : S131 - S141

← 1 2 3 4 5 →